KS 101
Alternative Names: KS-101; KS101-AD; KS101-CKDLatest Information Update: 09 Oct 2025
At a glance
- Originator Klotho Sciences
- Class Antidementias; Small molecules; Urologics
- Mechanism of Action KLB protein stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Renal failure
Most Recent Events
- 09 Oct 2025 Klotho Sciences intends to initiate phae IIa studies in Alzheimer's disease and Renal failure by December 2026 (Klotho Sciences pipeline, October 2025)
- 09 Oct 2025 Klotho Sciences intends to initiate phase I trials in Alzheimer's disease and Renal failure by December 2025 (Klotho Sciences pipeline, October 2025)
- 03 Sep 2025 Preclinical trials in Alzheimer's disease in South Korea (PO), prior to September 2025 (Klotho Sciences pipeline, September 2025)